Drug
Florensocatib clinical trials
Also written HSK31858 and CHF10196.
- studies test it
- 13
- open now
- 8
- in phase 3
- 3
- first study started
- 2021
Keep track of what changes. Save the florensocatib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Haisco Pharmaceutical Group Co., Ltd. (9) · Chiesi Farmaceutici S.p.A. (3) · Xizang Haisco Pharmaceutical Co., Ltd (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses florensocatib is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower CholesterolNot yet recruitingPhase 1Chiesi Farmaceutici S.p.A.NCT07744386Written as CHF10196
- A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male ParticipantsNot yet recruitingPhase 1Chiesi Farmaceutici S.p.A.NCT07683793Written as CHF10196
- A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With BronchiectasisNot yet recruitingPhase 3Chiesi Farmaceutici S.p.A.NCT07577804Written as CHF10196 tablets (florensocatib)
- A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisRecruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07616375Written as HSK31858, tablet
- Clinical Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HSK31858 in Healthy SubjectsEnrolling by invitationPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT07134465Written as HSK31858 Tablets and Itraconazole Capsules
- A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus HypersecretionEnrolling by invitationPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06820749Written as HSK31858
- A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial AsthmaEnrolling by invitationPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT06637254Written as HSK31858
- A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisRecruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT06660992Written as HSK31858, tablet
- Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy SubjectsActive, not recruitingPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT07134478Written as HSK31858 Tablets On the morning of Day 1, a single dose of HSK31858 tablets 40 mg will be administered. Rifampicin capsules After a 5-day washout period, a single dose of rifampicin capsules 600 mg wi
- A Study of HSK31858 in Participants with Non-Cystic Fibrosis BronchiectasisCompletedPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT05601778Written as HSK31858
- Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects.Active, not recruitingPhase 1Xizang Haisco Pharmaceutical Co., LtdNCT06569784Written as [14C]HSK31858
- Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy VolunteersCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT05663593Written as HSK31858, tablet
- A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy VolunteersCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT05023525Written as HSK31858, tablet
Codes
What other systems call florensocatib · ClinicalTrials.gg INT017825
- UNII (FDA) RWC743JRK7FLORENSOCATIBConfirmed FDA, Wikidata
- Wikidata Q140529169florensocatibConfirmed FDA, Wikidata
- NCI Thesaurus C215250FlorensocatibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | RWC743JRK7 | FLORENSOCATIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529169 | florensocatib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C215250 | Florensocatib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.